Dr. Douglas Dieterich: “Merck Challenges Harvoni with New Hepatitis C Treatment”
Powerful new Merck compounds have taken the fight against Hepatitis C to a new level. Combination therapy with grazoprevir/elbasvir in once-daily tablets showed high cure rates in research published today in the Annals of Internal Medicine for genotypes 1 (the most common) as well as genotypes 4 and 6. When combined with Gilead’s Sovaldi (sofosbuvir) in another study (C-SWIFT), the treatment showed “spectacular results,” according to Douglas Dieterich, MD, of the Icahn School of Medicine at Mount Sinai in New York City. Learn more
Researchers Identify Potential Target for Treatment Among Patients With Type 2 Diabetes
Aug 04, 2022 View All Press Releases
Mount Sinai Researcher Receives Prestigious International Award
Jul 06, 2022 View All Press Releases
